Biorestorative Therapies, Inc. · NASDAQ:BRTX
Biorestorative Therapies — Marcum Microcap Conference 2015
22 slides from Biorestorative Therapies's conference presentation, May 27, 2015
Slide 1: BioRestorative Therapies: A Stem Cell Biotechnology Company
BioRestorative Therapies: A Stem Cell Biotechnology Company MARCUM MICROCAP CONFERENCE Mark Weinreb, CEO May 2015
Slide 2: Forward-looking statements
This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including statements concerning the ability of BioRestorative Therapies, Inc. (the “Company”) to develop its adult stem cell business, the future of regenerative medicine and the role of adult
Slide 3: BioRestorative Therapies develops therapeutic products using adult stem cells
@ BioRestorative Therapies, Inc. (“BRT”) develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells @ Expertise in cell biology and cell culturing @ Research and development focused on cell-based therapies: * | DisclSpine (brixDISC™ ) *
Slide 4: Program Timing
Program Timing lS REELS brixDISC™ IND Submission’ approval tad Pre-IND meeting ThermoStem* e Pre-IND meeting
Slide 5: Addressing the Pathophysiology and Symptoms of Intervertebral Disc Disease
Nel Addressing the Pathophysiology and Symptoms of Intervertebral Disc Disease = Autologous mesenchymal stem cells for the treatment of chronic Lumbar Disc Disease (cLDD) = Successful pre-IND meeting with FDA m= Expected advancement of program into clinical trials by Q1 2016 biorestordtlve’ therapie
Slide 6: Today's Treatments Do Not Address Disease Pathology
Today’s Treatments Do Not Address Disease Pathology Surgical Treatments Non-Surgical Treatments Physical therapy and weight loss Non-steroidal anti-inflammatory drugs Spinal manipulation (chiropractic care) Epidural steroid injections Surgery (percutaneous, minimally invasive, fusion/disc replacemen
Slide 7: Lower Back Pain Market Opportunity
Lower Back Pain Market Opportunity US Market Size > $90B Oncein lifetime: 84% Chronic: 11% Cost Comparison Current surgical options may be >$100,000 Office-based BRT procedure es m™ At$15,000 price per procedure (private pay) + $7,500 of revenue to BRT * $5,000 of revenue to physician * $2,500 of di
Slide 8: Program objective, progress and near-term priorities
Program objective Background and Progress To Date Near-Term Priorities Advance lead cell therapy candidate, brtxDISC™, our anchor product for the Disc/Spine program Expect to enter clinical trials by Q1 2016 History of human clinical use lends high degree of confidence of ultimate achievement « Mult
Slide 9: brtxDISC: Treatment Process
brtxDISC™: Treatment Process
Slide 10: Spine MRIs of Patient Treated with brtxDISC
Spine MRIs of Patient Treated with brtxDISC™ J Stem cells may have a significant impact on the morphology of the disc and bring relief of symptoms
Slide 11: Target physicians trained in performing spinal injections
Target physicians are those trained and skilled in performing spinal injections + Interventional physiatrists (physical medicine physicians) + Pain management — anesthesiologists + Interventional radiologists + Neurosurgeons
Slide 12: Gregory E. Lutz, M.D.
Gregory E. Lutz, M.D. BRT Chief Medical Advisor for Spine Medicine = Physiatrist-in-Chief Emeritus for Hospital for Special Surgery (HSS) and a member of the Board of Trustees = Regenerative Medicine clinical trial experience = Associate Professor of Clinical Rehabilitation Medicine, Weill Medical C
Slide 13: Targets: pre-clinical, clinical trial preparation, manufacturing
TARGET = Finalize productformulation Pre-Clinical 42015 = Complete requiredanimal studies = Compile all required data for IND filing Finalize protocol and procedures Engage Contract Research Organization (CRO) Hire Director, Clinical Trial Ops Identify and engage potential trial sites and investigat
Slide 14: Brown adipose tissue preclinical program
= Brown adipose tissue preclinical program for the treatment of metabolic disorders = Pfizer collaboration on development of human brown adipose cells = Cell-based approach — brown adipose- derived stem cells = Target indications: obesity and type 2 diabetes = Potential biologic discovery program bi
Slide 15: Metabolic Syndrome
Metabolic Syndrome biorestorat therap
Slide 16: Obesity rates and new diabetes cases
Obesity Rates In Selected Countries New Diabetes US cases annually (MM) 35% usA 17 30% is 25% 20% England pa Australia P 15% Canada ; Spain io% os France 5% o% + ‘ 1970 1980 1990 2000 2010 88 94 oo 6 2 Seure: OECD. The cbesty epdemis: Anais of past and projected flue trends in slated OECD Sourve: CD
Slide 17: Program objective and progress to date
Program : eer Advance pre-clinical development leading to filing of IND Objective « Demonstrate that brown adipose tissue (BAT) derived from differentiated human stem cells can be used to treat or prevent metabolic disorders and restore metabolic homeostasis Progress ™ Established unique human brown
Slide 18: Metabolically Active Human Brown Adipose Tissue-Derived Stem Cells
Volume 32, Number 2, Februcry 2014 572. Metabolically Active Human Brown Adipose Tissue-Derived Stem Cells Francisco J Silva, Dolly J Holt, Vanessa Vargas et al. - Ahad Tress =a ae eek sion on biorestordt\ve" therapies
Slide 19: Pfizer collaboration study
ort = Jointly conducting a study entitled “Development and Validation of a Human Brown Adipose Cell Model” = BRT will leverage its human brown adipose tissue sample collection, pre-adipocyte cell lines and immortalized cell lines = Characterization of identity and metabolic function of cell lines bi
Slide 20: Options for delivery mechanism and indication
Options for Delivery Mechanism Indication Strengthen Program Use existing encapsulation technology already deployed in FDA trials Alternative existing encapsulation technology Creation of in-house developed device Orphan disease option * Accelerated clinical development path * Collection of data rel
Slide 21: Core Programs
CORE PROGRAMS —™ DISC/SPINE PROGRAM (b6rtxDISC™): « Complete requirements to submit IND and commence trials « Develop additional brtxDISC™ indications ™ METABOLIC PLATFORM PROGRAM (ThermoStem®): « Finalize clinical indication and delivery mechanism and drive to IND filing * Develop biologics program
Slide 22: BioRestorative Therapies
biorestordtlve herapies OTCQB: BRTX ¢ biorestorative.com biorestordtlve’ therapies
BioRestorative Therapies — Marcum Microcap Conference 2015 on 6ix